The University of Texas MD Anderson Cancer Center | Strategic Alliance Partners

Samer A. Srour, MB ChB, MS, discusses efficacy and safety data for the allogeneic CAR T-cell therapy CTX130 in advanced clear cell renal cell carcinoma.

Saruparib's favorable activity and safety may allow patients with advanced solid tumors to stay on treatment longer vs other approved PARP inhibitors.

Adagrasib plus cetuximab elicited a 34% objective response rate in patients with previously treated KRAS G12C-mutant advanced colorectal cancer.

Dr Jabbour expands on the FDA approval of ponatinib for patients with Ph-positive ALL, the agent’s mechanism of action, and data from the PhALLCON trial.

The anti-CD70 CAR T-cell therapy CTX130 showed activity and manageable toxicities in advanced renal cell carcinoma.

Michael R. Migden, MD, discusses efficacy data for RP1 in advanced non-melanoma skin cancer after prior solid organ transplant.

Krina K. Patel, MD, MSc, discusses the FDA approval of ide-cel for patients with triple class–exposed relapsed/refractory multiple myeloma.

Debu Tripathy, MD, discusses the current treatment paradigm of HER2-positive breast cancer and highlights unmet needs that remain.

Voruciclib plus venetoclax had antileukemic activity with acceptable safety in patients with relapsed or refractory acute myeloid leukemia.

Strickler, Leung, Dasari, and O'Neill discuss adverse effect monitoring and management with standard agents for patients with colorectal cancer.

Anna Lee, MD, MPH, discusses key takeaways from a presentation on managing head and neck cancers that was given at the 2024 ACRO Summit.

Elias Jabbour, MD, discusses the FDA approval of ponatinib plus chemotherapy for Philadelphia chromosome–positive acute lymphoblastic leukemia.

Sara Corvigno, MD, PhD, discusses the incidence of chemotherapy-related clonal hematopoiesis of indeterminate potential in patients with ovarian cancer.

Stereotactic ablative radiotherapy has shown clinical benefit in combination with immunotherapy in early-stage NSCLC, making it a viable treatment to consider.

Debu Tripathy, MD, discusses current considerations for the management of early-stage HER2-positive breast cancer.

Debu Tripathy, MD, provides insights on the management of HER2-positive breast cancer, including the evolving role of trastuzumab in this population.

Jennifer K. Litton, MD, discusses challenges determining the optimal sequencing of PARP inhibitors in early-stage triple-negative breast cancer.

Christina L. Roland, MD, MS, FACS, discusses a study of neoadjuvant immune-checkpoint blockade in retroperitoneal dedifferentiated liposarcoma.

Neil D. Gross, MD, FACS, discusses key safety data from a phase 2 study of neoadjuvant cemiplimab in cutaneous squamous cell carcinoma.

Michael J. Overman, MD, discusses the potential advantages of using nonoperative immunotherapy-based approaches in select gastrointestinal cancers.

Hans C. Lee, MD, discusses the significance of longer-term data for linvoseltamab from the LINKER-MM1 study in relapsed/refractory multiple myeloma.

In case you missed it, read a recap of every episode of OncLive On Air recorded in January 2024.

Jeremy L. Ramdial, MD, discusses the myeloablative conditioning regimen gemcitabine, clofarabine, and busulfan in patients with aggressive lymphomas.

Neil D. Gross, MD, FACS, discusses a phase 2 study evaluating neoadjuvant cemiplimab in cutaneous squamous cell carcinoma.

Dr Tripathy discusses the unique aspects of the Miami Breast Cancer Conference that make it worth returning to year after year.

Michael J. Overman, MD, discusses the potential use of endoscopy and ctDNA to guide nonoperative management approaches in gastrointestinal cancers.

Eleonora Dondossola, PhD, discusses the importance of studying bone metastasis in RCC and other genitourinary cancers.

The expert panel concludes their discussion with clinical insights on treatment sequencing and therapeutic decision-making for patients who have relapsed.

A roundtable discussion on the evolving treatment landscape surrounding CAR T-cell therapy in multiple myeloma, with a focus on future directions and the management of adverse events.

The expert panel discusses recent clinical trial data on GPRC5D-targeting bispecific antibodies and how they apply to the multiple myeloma treatment paradigms.